PDS Biotechnology Corporation (PDSB)
Automate Your Wheel Strategy on PDSB
With Tiblio's Option Bot, you can configure your own wheel strategy including PDSB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PDSB
- Rev/Share 0.0
- Book/Share 0.5519
- PB 2.6274
- Debt/Equity 0.8479
- CurrentRatio 2.3251
- ROIC -20.6264
- MktCap 66279500.0
- FreeCF/Share -0.8428
- PFCF -1.9407
- PE -1.6553
- Debt/Assets 0.4032
- DivYield 0
- ROE -1.5059
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
PDS Biotech announced the publication of three Versamune® HPV abstracts that were presented during the Head and Neck Cancer Poster Session at ASCO 2025.
Read More
PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
Phase 2: Versamune ® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC
Read More
PDS Biotechnology Corporation (PDSB) Q1 2025 Earnings Call Transcript
Published: May 14, 2025 by: Seeking Alpha
Sentiment: Neutral
PDS Biotechnology Corporation (NASDAQ:PDSB ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Frank Bedu-Addo - CEO Lars Boesgaard - CFO Kirk Shepard - Chief Medical Officer Mike Moyer - IR, LifeSci Advisors Conference Call Participants Mayank Mamtani - B. Riley Securities Joseph Pantginis - H.C.
Read More
PDS Biotechnology Corporation (PDSB) Q4 2024 Earnings Call Transcript
Published: March 27, 2025 by: Seeking Alpha
Sentiment: Neutral
PDS Biotechnology Corporation (NASDAQ:PDSB ) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Tom Johnson - LifeSci Advisors Frank Bedu-Addo - CEO Kirk Shepard - Chief Medical Officer Lars Boesgaard - CFO Conference Call Participants Joseph Pantginis - H.C. Wainwright Mayank Mamtani - B.
Read More
PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
PRINCETON, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, will present at the 2025 Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer Conference in New Orleans on Friday, March 28 – Saturday, March 29, 2025.
Read More
EMV Capital portfolio company PDS Biotechnology raises $11mln
Published: February 28, 2025 by: Proactive Investors
Sentiment: Positive
EMV Capital plc (AIM: EMVC) portfolio company PDS Biotechnology Corporation (Nasdaq: PDSB) has raised $11 million, through an equity funding. PDS, which is focussed on immunotherapies, sold around 7.33 million new shares in a direct offer, plus warrants which (if exercised) will bring in another $11 million.
Read More
PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced it has entered into securities purchase agreements with new and existing healthcare focused institutional investors as well as participation from certain directors of the Company, for the purchase and sale of 7,330,121 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 7,330,121 shares of common stock in a registered direct offering priced at-the-market …
Read More
PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Median Overall Survival (mOS) of 42.4 months in immune checkpoint inhibitor naïve patients; Historical published result is 7-12 months Continued survival in the cohort of HPV16-positive immune checkpoint inhibitor naïve patients - mOS not yet reached Median OS of 17 months in HPV16-positive immune checkpoint inhibitor resistant patients; Historically published result is 3-4 months Significant tumor shrinkage with confirmed objective response rate (ORR) of 75% in HPV16-positive immune checkpoint inhibitor naïve patients; Historically published result is 11-24% PRINCETON, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused …
Read More
PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
Data confirms Versamune ® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025
Read More
PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
PRINCETON, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech will participate in a fireside chat at the B.
Read More
About PDS Biotechnology Corporation (PDSB)
- IPO Date 2015-09-30
- Website https://www.pdsbiotech.com
- Industry Biotechnology
- CEO Frank K. Bedu-Addo
- Employees 24